P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)

por Vorobyev, V., Yoon, D. H., Kaźmierczak, M., Grosicki, S., Tarella, C., Genua, A., Kim, J. S., Cohan, D., Daugherty, M., Flinn, I. W., Zinzani, P. L., Gordon, L. I.
Publicado 2022

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HOD...

por Hernandez-Ilizaliturri, F. J., Kuruvilla, J., Christian, B. A., Flinn, I. W., Assouline, S. E., Ulrickson, M. L., Landsburg, D. J., Stuart, M., Lowman, H., Levin, N., Maetzel, D., Viller, N. N., MacLaren, A.
Publicado 2022

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES

por Shadman, M., Flinn, I. W., Kingsley, E. C., Freeman, B., Levy, M. Y., Cultrera, J., Farber, C. M., Chaudhry, A., Porter, R., Crescenzo, R., Idoine, A., Zhang, X., Cohen, A., By, K., Huang, J., Sharman, J. P.
Publicado 2022

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

por Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M
Publicado 2016

P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY

por Trněný, M., Fogliatto, L., Gardner, F., Flinn, I., Larouche, J.-F., Haioun, C., Canales, M., Goto, H., Hajek, R., Salles, G., Qiu, J., Campinha-Bacote, A., Yan, M., Kothari, R., Man, G., Sahin, D., Hirata, J., Lee, C., Tilly, H., Flowers, C.
Publicado 2022

P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 ST...

por Lee, H., Flinn, I. W., Melear, J., Ramchandren, R., Friedman, J., Burke, J. M., Linhares, Y., Raval, M., Chintapatla, R., Feldman, T. A., Yimer, H., Islas-Ohlmayer, M., Dean, A., Rana, V., Gandhi, M. D., Renshaw, J., Gillespie-Twardy, A. L., Ho, L., Puhlmann, M., Guo, W., Yasenchak, C. A.
Publicado 2022

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2

por Wang, M. L., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Flinn, I. W., Miklos, D. B., Pagel, J. M., Kersten, M. J., Houot, R., Beitinjaneh, A., Peng, W., Fang, X., Shen, R. R., Siddiqi, R., Kloos, I., Reagan, P. M.
Publicado 2022

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

por Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech-Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.
Publicado 2022